BRNS
Barinthus Biotherapeutics plc.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Sep 9. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 2 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.290 → −$0.260 over 90 days. 0 up, 1 down in 30 days.
- Short sellersBUILDING
Short interest +46.2% to 13.2K shares. 1.0 days to cover, ≈0.0% of shares.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | DOUBLED | $71.8K |
| CITADEL ADVISORS LLC | TRIM | $50.7K |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | $16.5K |
| MORGAN STANLEY | TRIM | $1.3K |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $100.2K |
| MORGAN STANLEY | TRIM | $2.4K |
| UBS Group AG | DOUBLED | $2.2K |
| Baird Financial Group, Inc. | TRIM | $134.3K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Nov 2025| Date | Firm | Rating |
|---|---|---|
| Nov 17, 2025 | HC Wainwright & Co. MAINTAIN | Buy |
| Mar 21, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Jan 13, 2025 | HC Wainwright & Co. MAINTAIN | Buy |
| Nov 19, 2024 | HC Wainwright & Co. REITERATE | Buy |
| Nov 8, 2024 | HC Wainwright & Co. REITERATE | Buy |
| Oct 1, 2024 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Sep 9, 2026 | DAWES KAREN A Director | TO ISSUER | 1,700 sh |
| Sep 9, 2026 | DAWES KAREN A Director | TO ISSUER | 19,516 sh |
| Sep 9, 2026 | DAWES KAREN A Director | TO ISSUER | 34,328 sh |
| Sep 9, 2026 | DAWES KAREN A Director | TO ISSUER | 18,604 sh |
| Sep 9, 2026 | DAWES KAREN A Director | TO ISSUER | 20,174 sh |
| Sep 9, 2026 | DAWES KAREN A Director | TO ISSUER | 19,197 sh |
| Sep 9, 2026 | Enright William Chief Executive Officer | TO ISSUER | 514,923 sh |
| Sep 9, 2026 | Phillips Anne M. Director | TO ISSUER | 3,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.26 | -$0.27–-$0.25 | +10.3% | $0.00 |
| Next Q | -$0.27 | -$0.27–-$0.26 | +14.5% | $0.00 |
| Current FY | -$0.92 | -$0.93–-$0.90 | +20.4% | $0.00 |
| Next FY | -$1.14 | -$1.20–-$1.07 | +1.3% | $0.00 |
Short side
FINRA· Aug 31, 2026SecBot reports
4 filings · 1 press release · 0 bullish · 1 bearish · 1 mixed · 2 neutral- NEUTRAL EFFECTSep 15, 2026
Barinthus Biotherapeutics plc's registration statement has become effective, allowing the company…
Monitor for the company's next pricing announcement or prospectus supplement to determine the offering size and terms. The effectiveness enables share sales, so watch for potential dilution pressure…
- MIXED 8-KAug 25, 2026
Barinthus Biotherapeutics (BRNS) is being acquired by Clywedog Therapeutics in an all-stock…
BRNS holders should prepare for the cessation of trading on September 3, 2026, and the conversion of their shares into the new entity, CLYD. The 0.111 exchange ratio is now fixed. Monitor the court…
- BEARISH 8-KJul 2, 2026
Barinthus Biotherapeutics received a 180-day extension from Nasdaq, until December 28, 2026, to…
The 180-day extension provides a temporary reprieve, but the transfer to the Nasdaq Capital Market signals ongoing distress. Monitor for a reverse stock split announcement or other compliance…
- NEUTRAL 3May 1, 2026
Douglas J. Swirsky filed a Form 3 initial statement of beneficial ownership as the new Principal…
Monitor for subsequent Form 4 filings to see if Swirsky acquires shares, which could signal insider sentiment.
All BRNS filing & press-release reports (5)
- EFFECT reportSep 15, 2026
- 8-K reportAug 25, 2026
- 8-K reportJul 2, 2026
- 3 reportMay 1, 2026
- PRESS-RELEASE reportMar 13, 2026